Alexander Sapir | executive |
Alan Musso | executive |
Corinne Jenkins | analyst |
Iain Fraser | executive |
Kristen Kluska | analyst |
Joseph Schwartz | analyst |
Dae Gon Ha | analyst |
Gregory Renza | analyst |
Matthew Biegler | analyst |
Good morning and welcome to Fulcrum's Therapeutics Second Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions] This call is being webcast live, and can be accessed on the Investors section of Fulcrum's website at www.fulcrumtx.com, and is being recorded. Please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about the company's future expectations and plans, clinical development timelines and financial projections.
While these forward-looking statements represent Fulcrum's view as of today, this should not be relied upon as representing the company's views in the future.